**Supplementary material**

**Table S1-1 Characteristics of included studies**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** |  **PCSK9 inhibitors** | **control** | **Mean age(years)** |  | **No. of patients** |  |  **Follow****up(weeks)** |
| **PCSK9 inhibitors** | **control** | **PCSK9 inhibitors** | **control** |
| **ODYSSEY ALTERNATIVE [S1]** | alirocumab 150mg/2W | ezetimibe | 64.1±9.0 | 62.8±10.1 |  | 126 | 125 |  | 24 |
| **ODYSSEY CHOICE I [S2]** | alirocumab300mg/4W | placebo | 61.6±10.0 | 61.6±9.7 |  | 312 | 157 |  | 24 |
| **ODYSSEY CHOICE II [S3]** | alirocumab75mg/2W | placebo | 62.5±9.9 | 63.1±10.7 |  | 116 | 58 |  | 32 |
| **ODYSSEY COMBO I [S4]** | Alirocumab75mg/2W | placebo | 63.0±9.5 | 63.0±8.8 |  | 209 | 107 |  | 52 |
| **ODYSSEY COMBO II [S5]** | Alirocumab75mg/2W | ezetimibe | 61.7±9.4 | 61.3±9.2 |  | 479 | 241 |  | 52 |
| **ODYSSEY DM-DYSLIPIDEMIA [S6]** | Alirocumab75-150mg/2W | Usual care | 62.8±9.3 | 64.1±8.8 |  | 276 | 137 |  | 24 |
| **ODYSSEY DM-INSULIN [S7]** | Alirocumab150mg/2W | Placebo | 63.9±8.9 | 64.0±9.4 |  | 294 | 147 |  | 24 |
| **ODYSSEY ESCAPE [S8]** | Alirocumab75-150mg/2W | Placebo | 59.5±9.2 | 57.0±10.5 |  | 41 | 21 |  | 18 |
| **ODYSSEY FH I [S9]**  | Alirocumab75-150mg/2W | Placebo | 52.1±12.9 | 51.7±12.3 |  | 322 | 163 |  | 24 |
| **ODYSSEY FH II [S9]** | Alirocumab75-150mg/2W | Placebo | 53.2±12.9 | 53.2±12.5 |  | 167 | 82 |  | 24 |
| **ODYSSEY HIGH FH [S10]** | Alirocumab150mg/2W | Placebo | 49.8±14.2 | 52.1±11.2 |  | 72 | 35 |  | 24 |

**Table S1-2 Characteristics of included studies**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** |  **PCSK9 inhibitors** | **control** | **Mean age(years)** |  | **No. of patients** |  |  **Follow****up(weeks)** |
| **PCSK9 inhibitors** | **control** | **PCSK9 inhibitors** | **control** |
| **ODYSSEY JAPAN [S11]** | alirocumab 75-150mg/2W | placebo | 60.3±9.7 | 61.8±9.0 |  | 144 | 72 |  | 24 |
| **ODYSSEY KT [S12]** | alirocumab75-150mg/2W | placebo | 61.2±10.4 | 60.1±9.1 |  | 97 | 102 |  | 24 |
| **ODYSSEY LONG TERM [S13]** | alirocumab150mg/2W | placebo | 60.4±10.4 | 60.6±10.4 |  | 1553 | 788 |  | 78 |
| **ODYSSEY MONO [S14]** | Alirocumab75mg-150/2W | Ezetimibe10mg/d | 60.8±4.6 | 59.6±5.3 |  | 52 | 51 |  | 24 |
| **ODYSSEY OPTIONS I [S15]** | Alirocumab75mg-150mg/2W | Ezetimibe10mg/d | 62.2±10.0 | 65.7±9.0 |  | 57 | 55 |  | 24 |
| **ODYSSEY OPTIONS II [S16]** | Alirocumab75mg-150mg/2W | Ezetimibe10mg/d | 62.2±11.1 | 60.4±10.4 |  | 49 | 48 |  | 24 |
| **ODSSEY OUTCOMES [S17]** | Alirocumab75mg-150mg/2W | placebo | 58.5±9.3 | 58.6±9.4 |  | 9462 | 9462 |  | 134 |
| **McKenney JM [S18]** | Alirocumab150mg/2W | placebo | 59.9±11.1 | 53.3±8.5 |  | 31 | 31 |  | 12 |
| **Teramoto T [S19]** | Alirocumab150mg/2W | placebo | 58.2±8.8 | 58.6±9.2 |  | 25 | 25 |  | 12 |
| **Stein EA [S20]** | Alirocumab150mg/2W | placebo | 56.3±10.2 | 51.9±9.6 |  | 16 | 15 |  | 12 |
| **Roth EM [S21]** | AlirocumabNR | placebo | 57.6±9.3 | 55.3±10.3 |  | 30 | 31 |  | 8 |

**Table S1-3 Characteristics of included studies**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **PCSK9 inhibitors** | **control** | **Mean age(years)** |  | **No. of patients** |  |  **Follow****up(weeks)** |
| **PCSK9 inhibitors** | **control** | **PCSK9 inhibitors** | **control** |
| **LAPLACE-TIMI 57 [S22]** | Evolocumab 140mg/2W | placebo | 63.5 | 61.0 |  | 78 | 78 |  | 12 |
| **MENDEL [S23]** | Evolocumab 140mg/2W | placebo | 52.8±11.6 | 52.5±9.8 |  | 45 | 45 |  | 12 |
| **DESCARTES [S24]** | Evolocumab 420mg/4W | placebo | 55.9±10.8 | 56.7±10.1 |  | 599 | 302 |  | 52 |
| **EBBINGHAUS [S25]** | Evolocumab 140mg/2W  | placebo | 62.9±8.7 | 62.7±8.7 |  | 983 | 990 |  | 24 |
| **FOURIER [S26]** | Evolocumab140mg/2W or420mg/4W | placebo | 62.5±9.1 | 62.5±8.9 |  | 13784 | 13780 |  | 105 |
| **GAUSS [S27]** | Evolocumab420mg/4W | placebo | 62.0±7.2 | 62.4±6.6 |  | 30 | 32 |  | 12 |
| **GAUSS-2 [S28]** | Evolocumab 140mg/2W | Ezetimibe10mg/d | 61.0±10.0 | 62.0±10.0 |  | 103 | 51 |  | 12 |
| **GAUSS-3 [S29]** | Evolocumab 420mg/4W | Ezetimibe10mg/d | 59.0±11.1 | 58.5±9.4 |  | 145 | 73 |  | 24 |
| **GAUSS-4 [S30]** | Evolocumab 140mg/2W or420mg/4W | Ezetimibe 10mg/d | 65.8±9.8 | 61.8±11.9 |  | 40 | 41 |  | 12 |
| **GLAGOV [31]** | Evolocumab 420mg/4W | placebo | 59.8±9.6 | 59.8±8.8 |  | 484 | 484 |  | 76 |
| **OSLER [32]** | Evolocumab420mg/4W | placebo | 57.8±11.0 | 58.2±10.9 |  | 2976 | 1489 |  | 48 |

**Table S1-4 Characteristics of included studies**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **PCSK9 inhibitors** | **control** | **Mean age(years)** |  | **No. of patients** |  |  **Follow****up(weeks)** |
| **PCSK9 inhibitors** | **control** | **PCSK9 inhibitors** | **control** |
| **YUKAWA [S33]** | Evolocumab 140mg/2W | placebo | 60.8±9.2 | 60.2±10.1 |  | 52 | 52 |  | 12 |
| **YUKAWA-2 [S34]** | Evolocumab 140mg/2W | placebo | 61.8±11.9 | 60.4±10.4 |  | 51 | 52 |  | 12 |
| **EVOPACS [S35]** | Evolocumab 140mg/2W | placebo | 60.5±12.0 | 61.0±10.7 |  | 155 | 153 |  | 8 |
| **LAPLACE-2 [S36]** | Evolocumab 140mg/2W or420mg/4W | placebo | 59.6±9.9 | 59.9±10.2 |  | 1117 | 558 |  | 12 |
| **MENDEL-2 [S37]** | Evolocumab 140mg/2W | placebo | 53.0±14 | 54.0±10 |  | 153 | 76 |  | 12 |
| **RUTHERFORD [S38]** | Evolocumab 420mg/4W | placebo | 51.8±13 | 49.3±11.3 |  | 56 | 56 |  | 12 |
| **RUTHERFORD-2 [S39]** | Evolocumab140mg/2W | placebo | 52.6±12.3 | 51.1±14.2 |  | 110 | 54 |  | 12 |
| **TESLA Part B [S40]** | Evolocumab 420mg/4W | placebo | 30.0±12.0 | 32.0±14.0 |  | 33 | 16 |  | 12 |
| **ANITSCHKOW [S41]** | Evolocumab420mg/4W | placebo | 60.0±6.8 | 60.7±7.6 |  | 65 | 64 |  | 12 |
| **FLOREY [S42]** | Evolocumab 420mg/2W | placebo | 33.5±11.6 | 33.9±12.7 |  | 23 | 22 |  | 8 |
| **SPIRE [S43]** | Bococizumab150mg/2W | placebo | 62.9 | 63.0 |  | 13720 | 13718 |  | 40 |

**Table S1-5 Characteristics of included studies**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **PCSK9 inhibitors** | **control** | **Mean age(years)** |  | **No. of patients** |  |  **Follow****up(weeks)** |
| **PCSK9 inhibitors** | **control** | **PCSK9 inhibitors** | **control** |
| **Ridker PM [S44]** **SPIRE-HR** **SPIRE-LDL****SPIRE-FH****SPIRE-LL****SPIRE-SI****SPIRE-AI** | Bococizumab150mg/2WBococizumab150mg/2WBococizumab150mg/2WBococizumab150mg/2WBococizumab150mg/2WBococizumab75-150mg/2W | PlaceboPlaceboPlaceboPlaceboPlaceboplacebo | 61.1±10.261.8±9.356.5±10.561.5±9.964.0±9.260.0±10.0 | 61.5±9.762.2±9.855.7±11.261.7±10.063.2±8.461.0±11.0 |  | 357106818549974200 | 35410711852477399 |  | 585858585818 |
| **Yokote K [S45]** | Bococizumab 150mg/2W | placebo | 59.6±8.6 | 58.2±11.2 |  | 22 | 26 |  | 16 |

**NR, no reported**

**Table S2 Search terms used for meta-analysis in MEDLINE, Cochrane Library database and Clinicaltrials.gov**

|  |  |
| --- | --- |
| **Concept** | **Search terms** |
| **PCSK9 inhibitors**  | **‘evolocumab’ or ‘AMG 145’ or ‘alirocumab’ or ‘SAR236553’ or ‘REGN727’ or ‘bococizumab’ or ‘RN316/PF-04950615’.**  |

**Supplementary References**

1. Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA8, Kopecky SL, Baccara-Dinet MT, Du Y, Pordy R, Gipe DA; ODYSSEY ALTERNATIVE InvestigatorsEfficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015,9:758-769.
2. Roth EM, Moriarty PM, Bergeron J, Langslet G, Manvelian G, Zhao J, Baccara-Dinet MT, Rader DJ; ODYSSEY CHOICE I investigators. A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I. Atherosclerosis. 2016,254:254-262.
3. Stroes E, Guyton JR, Lepor N, Civeira F, Gaudet D, Baccara-Dinet MT, Lecorps G, Manvelian G, Farnier M; ODYSSEY CHOICE II Investigators. Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. J Am Heart Assoc. 2016,5: e003421.
4. Kereiakes DJ, Robinson JG, Cannon CP, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. Am Heart J. 2015,169: 906-915.
5. Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM; ODYSSEY COMBO II Investigators. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEYCOMBO II randomized controlled trial. Eur Heart J. 2015, 36: 1186-1194.
6. Ray KK, Leiter LA, Müller-Wieland D, Cariou B, Colhoun HM, Henry RR, Tinahones FJ, Bujas-Bobanovic M, Domenger C, Letierce A, Samuel R, Del Prato S. Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial. Diabetes Obes Metab. 2018, 20: 1479-1489.
7. Leiter LA, Cariou B, Müller-Wieland D, Colhoun HM, Del Prato S, Tinahones FJ, Ray KK, Bujas-Bobanovic M, Domenger C, Mandel J, Samuel R, Henry RR. Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial. Diabetes Obes Metab. 2017,19:1781-1792.
8. Moriarty PM, Parhofer KG, Babirak SP, Cornier MA, Duell PB, Hohenstein B, Leebmann J, Ramlow W8, Schettler V, Simha V, Steinhagen-Thiessen E, Thompson PD, Vogt A, von Stritzky B, Du Y, Manvelian G. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur Heart J. 2016,37:3588-3595.
9. Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, Blom D, Civeira F, Krempf M, Lorenzato C, Zhao J, Pordy R, Baccara-Dinet MT, Gipe DA, Geiger MJ, Farnier M. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015,36:2996-3003.
10. Ginsberg HN, Rader DJ, Raal FJ, Guyton JR, Baccara-Dinet MT, Lorenzato C, Pordy R, Stroes E. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher. Cardiovasc Drugs Ther. 2016, 30:473-483.
11. Teramoto T, Kobayashi M, Tasaki H, Yagyu H, Higashikata T, Takagi Y, Uno K, Baccara-Dinet MT, Nohara A. Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins-ODYSSEY JAPAN Randomized Controlled Trial. Circ J. 2016,80:1980-1987.
12. Koh KK, Nam CW, Chao TH, Liu ME, Wu CJ, Kim DS, Kim CJ, Li I, Li J, Baccara-Dinet MT, Hsiao PJ, Chiang CE. A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT). J Clin Lipidol. 2018,12:162-172.
13. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ; ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015,372:1489-1499.
14. Roth EM, Taskinen MR, Ginsberg HN, Kastelein JJ, Colhoun HM, Robinson JG, Merlet L, Pordy R, Baccara-Dinet MT. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial. Int J Cardiol. 2014,176:55-61.
15. Bays H, Gaudet D, Weiss R, Ruiz JL, Watts GF, Gouni-Berthold I, Robinson J, Zhao J, Hanotin C, Donahue S. Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial. J Clin Endocrinol Metab. 2015,100:3140-3148.
16. Farnier M, Jones P, Severance R, Averna M, Steinhagen-Thiessen E, Colhoun HM, Du Y, Hanotin C, Donahue S. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular- risk patients: The ODYSSEY OPTIONS II randomized trial. Atherosclerosis. 2016,244:138-146.
17. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018,379:2097-2107.
18. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012,59:2344-2353.
19. Teramoto T, Kobayashi M, Uno K, Takagi Y, Matsuoka O, Sugimoto M, Inoue S, Minami F, Baccara-Dinet MT. Efficacy and Safety of Alirocumab in Japanese Subjects (Phase 1 and 2 Studies) . Am J Cardiol. 2016,118:56-63.
20. Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, Wu R, Pordy R. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012,380:29-36.
21. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia. N Engl J Med. 2012,367:1891-1900.
22. Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MS; LAPLACE-TIMI 57 Investigators. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012,380:2007-2017.
23. Koren MJ, Scott R, Kim JB, Knusel B, Liu T, Lei L, Bolognese M, Wasserman SM. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2012; 380: 1995–2006.
24. Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, Monsalvo ML, Tsirtsonis K, Kim JB, Scott R, Wasserman SM, Stein EA; DESCARTES Investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014;370:1809-1819.
25. Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, Schneider J, Wang H, Keech A, Pedersen TR1, Sabatine MS1, Sever PS, Robinson JG, Honarpour N, Wasserman SM, Ott BR; EBBINGHAUS Investigators. Cognitive Function in a Randomized Trial of Evolocumab. N Engl J Med 2017; 377: 633-643.
26. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017;376:1713-1722.
27. Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, Wasserman SM, Stein EA. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012,308:2497-2506.
28. Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, Bruckert E, Cho L, Dent R, Knusel B, Xue A, Scott R, Wasserman SM, Rocco M; GAUSS-2 Investigators. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 2014;63:2541-2548.
29. Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, Ceška R9, Lepor N10, Ballantyne CM11, Gouni-Berthold I12, Elliott M, Brennan DM, Wasserman SM, Somaratne R, Scott R, Stein EA; GAUSS-3 Investigators .Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA.2016;315(15):1580-1590.
30. Koba S, Inoue I, Cyrille M, Lu C, Inomata H, Shimauchi J, Kajinami K. Evolocumab vs. Ezetimibe in Statin-Intolerant Hyperlipidemic Japanese Patients: Phase 3 GAUSS-4 Trial. J Atheroscler Thromb. 2019 Nov 21. [Epub ahead of print]
31. Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA.2016;316:2373-2384.
32. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500-1509.
33. Hirayama A, Honarpour N, Yoshida M, Yamashita S, Huang F, Wasserman SM, Teramoto T. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study. Circ J. 2014;78:1073-1082.
34. Kiyosue A, Honarpour N, Kurtz C, Xue A, Wasserman SM, Hirayama A. A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk. Am J Cardiol. 2016;117:40-47.
35. Koskinas KC, Windecker S, Pedrazzini G, Mueller C, Cook S, Matter CM, Muller O, Häner J, Gencer B, Crljenica C, Amini P, Deckarm O, Iglesias JF, Räber L, Heg D, Mach F. Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS). J Am Coll Cardiol. 2019;74:2452-2462.
36. Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, Wasserman SM, Weiss R; LAPLACE-2 Investigators. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311:1870-1882.
37. Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, Kim JB, Scott R, Wasserman SM, Bays H; MENDEL-2 Investigators. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63:2531-2540.
38. Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, Stein EA. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012;126: 2408-2417.
39. Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I, Scott R, Wasserman SM, Gaudet D; RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015; 385: 331-340.
40. Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, Wasserman SM, Stein EA; TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015; 385: 341-50.
41. National Institutes of Health. ClinicalTrials.gov [Internet]. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a)) (ANITSCHKOW). National Institutes of Health; 2019. Identiﬁer NCT02729025. https://Clini calTrials.gov/show/ NCT02729025.
42. National Institutes of Health. ClinicalTrials.gov [Internet]. Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody (FLOREY). National Institutes of Health; 2018. Identiﬁer NCT 02189837. https://Clini calTrials.gov/show/ NCT 02189837.
43. Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC; SPIRE Cardiovascular Outcome Investigators. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. N Engl J Med. 2017;376:1527-1539.
44. Ridker PM, Tardif JC, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W1, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C; SPIRE Investigators. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. N Engl J Med. 2017;376:1517-1526.
45. Yokote K, Kanada S, Matsuoka O, Sekino H, Imai K, Tabira J, Matsuoka N, Chaudhuri S, Teramoto T. Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive-Results From a Randomized, Placebo-Controlled, Dose-Ranging Study. Circ J. 2017; 81: 1496-1505.